These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932 [TBL] [Abstract][Full Text] [Related]
4. Combination immunotherapy strategies for glioblastoma. Chan HY; Choi J; Jackson C; Lim M J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705 [TBL] [Abstract][Full Text] [Related]
5. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy. White K; Connor K; Meylan M; Bougoüin A; Salvucci M; Bielle F; O'Farrell AC; Sweeney K; Weng L; Bergers G; Dicker P; Ashley DM; Lipp ES; Low JT; Zhao J; Wen P; Prins R; Verreault M; Idbaih A; Biswas A; Prehn JHM; Lambrechts D; Arijs I; Lodi F; Dilcan G; Lamfers M; Leenstra S; Fabro F; Ntafoulis I; Kros JM; Cryan J; Brett F; Quissac E; Beausang A; MacNally S; O'Halloran P; Clerkin J; Bacon O; Kremer A; Chi Yen RT; Varn FS; Verhaak RGW; Sautès-Fridman C; Fridman WH; Byrne AT Ann Oncol; 2023 Mar; 34(3):300-314. PubMed ID: 36494005 [TBL] [Abstract][Full Text] [Related]
6. Allomelanin-based biomimetic nanotherapeutics for orthotopic glioblastoma targeted photothermal immunotherapy. Sun M; Li Y; Zhang W; Gu X; Wen R; Zhang K; Mao J; Huang C; Zhang X; Nie M; Zhang Z; Qi C; Cai K; Liu G Acta Biomater; 2023 Aug; 166():552-566. PubMed ID: 37236575 [TBL] [Abstract][Full Text] [Related]
7. CXCL10 and Nrf2-upregulated mesenchymal stem cells reinvigorate T lymphocytes for combating glioblastoma. Mao J; Li J; Chen J; Wen Q; Cao M; Zhang F; Li B; Zhang Q; Wang Z; Zhang J; Shen J J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056897 [TBL] [Abstract][Full Text] [Related]
8. Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade. De Waele J; Marcq E; Van Audenaerde JR; Van Loenhout J; Deben C; Zwaenepoel K; Van de Kelft E; Van der Planken D; Menovsky T; Van den Bergh JM; Willemen Y; Pauwels P; Berneman ZN; Lardon F; Peeters M; Wouters A; Smits EL Oncoimmunology; 2018; 7(3):e1407899. PubMed ID: 29399410 [TBL] [Abstract][Full Text] [Related]
9. Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics. Wei R; Li J; Lin W; Pang X; Yang H; Lai S; Wei X; Jiang X; Yuan Y; Yang R Acta Biomater; 2024 Mar; 177():414-430. PubMed ID: 38360292 [TBL] [Abstract][Full Text] [Related]
10. AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma. Strecker MI; Wlotzka K; Strassheimer F; Roller B; Ludmirski G; König S; Röder J; Opitz C; Alekseeva T; Reul J; Sevenich L; Tonn T; Wels WS; Steinbach JP; Buchholz CJ; Burger MC Oncoimmunology; 2022; 11(1):2127508. PubMed ID: 36249274 [TBL] [Abstract][Full Text] [Related]
11. Janus Silica Nanoparticle-Based Tumor Microenvironment Modulator for Restoring Tumor Sensitivity to Programmed Cell Death Ligand 1 Immune Checkpoint Blockade Therapy. Lin X; Li F; Guan J; Wang X; Yao C; Zeng Y; Liu X ACS Nano; 2023 Aug; 17(15):14494-14507. PubMed ID: 37485850 [TBL] [Abstract][Full Text] [Related]
12. The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade. Park JH; Kang I; Lee HK Front Immunol; 2022; 13():1044544. PubMed ID: 36591276 [TBL] [Abstract][Full Text] [Related]
13. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389 [TBL] [Abstract][Full Text] [Related]
14. The N Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G Front Immunol; 2021; 12():653711. PubMed ID: 34354698 [TBL] [Abstract][Full Text] [Related]